Cite
HARVARD Citation
Ueno, M. et al. (2021). A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy. Cancer medicine. pp. 2088-2099. [Online].